Key Findings
Advancing regulatory approval and commercialization
Digital therapeutics (DTx) and digital care (DC) products and tools - which incorporate software as a means to treat, prevent or manage specific diseases or conditions - have been proliferating, and more than 250 such products are now identified, including about 150 products that are commercially available.
Attachments
Original document
Permalink
Disclaimer
IQVIA Holdings Inc. published this content on 22 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 July 2021 03:36:01 UTC.
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows:
- development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes;
- development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers;
- integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc.
Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).
IQVIA HOLDINGS INC. 
